|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||19.13 - 19.13|
|52 Week Range||9.10 - 34.30|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||15.88|
|Forward Dividend & Yield||0.27 (1.41%)|
|Ex-Dividend Date||Jun 03, 2020|
|1y Target Est||N/A|
Syndax Pharmaceuticals reported on the first half-dozen patients to get a novel drug code-named SNDX-5613 that targets a mutation involved in some leukemias.
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing
Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.
In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline® Depot (lanreotide) redesigned pre-filled syringe
Health Canada approves CABOMETYX™ (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular Carcinoma
The results, which included preliminary safety and efficacy data, were presented as an oral presentation at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona , 7-10 September 2019 .
Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress ...
ADR: IPSEY) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Dysport® in the treatment of focal spasticity. Dr Stephen Ashford, Consultant Physiotherapist at Northwick Park Hospital, London said "We are delighted by this news and it means the role of the physiotherapist in administration of botulinum toxin for spasticity management is recognised.
The structure's credit enhancement is quantified by the maximum deterioration in property value that the securities are able to withstand under various stress scenarios without causing an increase in the expected loss for various rating levels. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.